Chugai Pharma USA Announces Appointment of Chief Medical Officer
PR Newswire - Fri Apr 25, 1:00AM CDT
Chugai Pharma USA, LLC (CPUSA), Berkeley Heights, NJ a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai) Tokyo, Japan, member of the Roche Group, appoints Athos Gianella-Borradori, M.D. as Chief Medical Officer of CPUSA.
What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Over the past five years, few drugs have been as highly anticipated as Gilead's Sovaldi, a new-generation oral treatment for hepatitis C infection. Sovaldi won FDA approval in December, and despite only being available for a few weeks, Sovaldi...
Fitch Affirms Merck & Co.'s Long-term IDR at 'A+'; Outlook Remains Negative
Business Wire - Thu Apr 24, 1:24PM CDT
Fitch Ratings has affirmed Merck & Co.'s (Merck) long-term ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating Outlook remains Negative. In addition, Fitch has affirmed the company's short-term ratings at 'F1'. A full list of rating actions follows at the end of this release.
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1516-100free.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Thu Apr 24, 6:42AM CDT
Merck KGaA (FRANKFURT: MRK)
Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - Thu Apr 24, 5:00AM CDT
I've covered these dividend winners before, but you're not too late to get on board.
Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...
Andrzej S. Krolewski, MD, PhD, Receives American Diabetes Association's Kelly West Award for Outstanding Achievement in Epidemiology
Marketwire - Wed Apr 23, 12:13PM CDT
The American Diabetes Association will present the Kelly West Award for Outstanding Achievement in Epidemiology to Andrzej S. Krolewski, MD, PhD. Supported by an unrestricted educational grant from Merck, this award is given to an individual who has made significant contributions to the field of diabetes epidemiology. Dr. Krolewski will be recognized with this honor at the Association's 74th Scientific Sessions(R), taking place June 13-17, 2014, at the Moscone Center in San Francisco.
Edward S. Horton, MD, Receives American Diabetes Association's Albert Renold Award
Marketwire - Wed Apr 23, 12:12PM CDT
The American Diabetes Association will present the Albert Renold Award to Edward S. Horton, MD. Supported by a grant from Merck, this award is presented to an individual whose career is distinguished by outstanding achievements in the training and mentorship of diabetes research scientists and in the facilitation of diabetes research. Dr. Horton will be recognized with this honor at the Association's 74th Scientific Sessions(R), taking place June 13-17, 2014, at the Moscone Center in San Francisco.
Gilead, Illumina Q1 Earnings Win Wall Street's Love
at Investor's Business Daily - Wed Apr 23, 10:39AM CDT
Analysts were singing the praises of life-science giants Gilead Sciences (GILD) and Illumina (ILMN) Wednesday morning after both surged above Q1 estimates late Tuesday. Shares of both companies were up on the stock market today. Gilead's $2.3 billion...
Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results
Say Hello to the New Fastest Growing Drug in History!
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 23, 9:03AM CDT
Take every guess you had as to how well Gilead Sciences would perform in the first-quarter, no matter how outrageous, and completely throw them out the window because Gilead would have trumped it! Break out your thesaurus because you'll need...
Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals
PR Newswire - Wed Apr 23, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy and Golden Globe-winning actress S. Epatha Merkerson on America's Diabetes Challenge: Get to Your Goals, an educational program intended to encourage people with type 2 diabetes to achieve better control of their blood sugar -- a key goal to help reduce the risk of serious health problems. Merkerson, who lives with type 2 diabetes, will travel the country urging people to know their A1C (average blood sugar level over the past two to three months) and to work with their doctors to set and attain their own A1C goal.
The COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014-2018
M2 - Wed Apr 23, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4stq5l/copd_drug_market) has announced the addition of the "COPD Drug Market Opportunity & Clinical Pipeline Analysis" report to their offering. The market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018 Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide. Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler. There has been significant expansion in the COPD drug market in the recent years and it is expected that this market would record high growth over the next decade. The major driving force in the future would be a greater demand for new drugs with higher and better efficiency. This market has been recognized to be one with many opportunities which are yet to be tapped. Hence, the leading pharma companies are increasing their focus on this segment by introducing new combination drugs and novel agents. The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Key Topics Covered: 1. Global Chronic Obstructive Pulmonary Disease Market Overview 2. EMA Guideline on Clinical Investigation of COPD Drugs 3. FDA Guideline on Clinical Investigation of COPD Drugs 4. Chronic Obstructive Pulmonary Disease Drug Clinical Trial by Phase & Country 5. Marketed Drugs for Chronic Obstructive Pulmonary Disease by Country 6. No Development, Discontinued & Suspended Drug Clinical Trial by Phase & Country 7. Competitive Landscape - Almirall - AstraZeneca, - Bayer - Boehringer Ingelheim, - Chiesi Farmaceutici - Forest Laboratories - Lallemand Pharma - Merck & Co - Novartis - Sunovion Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/4s...rug_market
Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019
M2 - Wed Apr 23, 2:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/35ctmw/hepatitis_c) has announced the addition of the "Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019" report to their offering. The global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy. In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon. A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, including several interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, the authors believe the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion. Scope - A brief introduction to hepatitis C, including the disease's pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms. - In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy. - A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target. - In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products. - Multi-scenario forecast data of the market to 2019, which takes into account the effects of the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets: US, Canada, Japan, Germany, UK, France, Italy and Spain. - Discussion of the drivers and barriers for market growth. - Analysis of licensing and co-development deals occurring in the hepatitis C market. Key Topics Covered: 1 Tables & Figures 2 Introduction - Signs and Symptoms - Etiology and Risk Factors - Pathophysiology - Epidemiology - Prognosis - Treatment 3 Marketed Products - Ribavirin - Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) - Hoffmann La Roche and Merck & Co - Incivek (telaprevir) - Vertex Pharmaceuticals and Janssen-Cilag - Victrelis (boceprevir) - Merck & Co - Olysio (simeprevir) - Johnson and Johnson - Sovaldi (sofosbuvir) - Gilead Sciences - Heat Map for Marketed Products 4 Developmental Pipeline - Overall Pipeline - Mechanisms of Action - Clinical Trials - Promising Pipeline Drugs - Heat Map and Competitor Matrix for Pipeline Products - Conclusion 5 Market Forecast to 2019 6 Drivers and Barriers 7 Licensing and Co-development deals 8 Appendix For more information visit http://www.researchandmarkets.com/research/35...epatitis_c
Asia shares mixed on lackluster China data
By ELAINE KURTENBACH - AP - Tue Apr 22, 11:08PM CDT
TOKYO (AP) — Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector.
Valeant, Ackman make $45.6B Allergan bid
AP - Tue Apr 22, 7:43PM CDT
NEW YORK (AP) — Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.
Drugmakers Prod European Stocks To Post-Easter Rally
at Investor's Business Daily - Tue Apr 22, 5:36PM CDT
European exchanges were high scorers on the world map Tuesday, as investors returned with vigor from the four-day holiday. Germany's Frankfurt Exchange led the pack, with the DAX index vaulting 2% higher. In Italy, Milano's FTSE MIB punched up 1.5%....